LONDON (Reuters) – Some of AstraZeneca's biggest investors are calling for a radical shake-up of the drugmaker's board and executive team, including the replacement of David Brennan as CEO, the Financial Times reported on Monday. The move …
Tags: Astrazeneca, Ceo, David Brennan, Executive Team, Financial Times, Investors, London Reuters, S Board